Prevalence of Upper Limb Musculoskeletal Abnormalities in Type 2 Diabetic Patients and Its Relation to Hypoglycemic Control.
NCT ID: NCT05819671
Last Updated: 2023-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2022-11-01
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
THE Effect of Tight Glycemic Control on Microvascular Complications in Type 2 Diabetes Mellitus
NCT07049601
Prevalence Of Oral Mucosal Alterations In Diabetes Mellitus Type2
NCT03670797
Diabetes Complications and Hearing Loss
NCT06190938
Comorbidities in Type 2 Diabetes Mellitus
NCT05874141
Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.
NCT03154398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria: patients will be included to this study(cases) if they are:
1\) Diabetic patients. 2) Age \> 18 years. 3) Diagnosed as type 2.
Exclusion criteria:
Patients will be excluded if they have rheumatoid arthritis, other rheumatological diseases or previous upper limb surgeries.
Sample size calculation: By reviewing literature, it is found that the most relevant study (3) to our work found that the prevalence of upper limb musculoskeletal abnormalities in type 2 diabetic patients is .22 and for control group is .05 so, by using piface calculator (version 1.76) to calculate sample size (power = 0.8, alpha error = 0.05 and beta= 0.2) it is found that we need 71 participants for every group. To increase power of the study will enroll 100 participants for every group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Groupe(A)
Group (A)diabetics - g
No interventions assigned to this group
group(B)
group B normal is a normal control(non-diabetics)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eslam Elsayed Ali Shohda
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eslam Elsayed Ali Shohda
General Committee of Teaching Hospitals and Institutes, Egypt
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eslam Dr Shohda, hd,pt
Role: PRINCIPAL_INVESTIGATOR
GOTHI
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Al ahrar teaching hospital
Zagazig, Sharqia Province, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAH00016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.